Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on November 12, 2021, at 8:30 AM ET to discuss its second quarter 2022 financial results and operational highlights. Interested participants can join by calling (877) 407-9716 (US) or (201) 493-6779 (internationally) using conference ID: 13723601, or by accessing the live webcast at Medicenna's website. The event will also feature an archive of the call after its conclusion.

Medicenna is a clinical stage immunotherapy company focused on innovative cancer treatments.

Positive

• Host of a conference call to discuss financial results indicates transparency.
• Focus on innovative therapies like MDNA11 and MDNA55 suggests potential for future growth.

Negative

• No specific financial metrics or guidance provided in the PR could indicate uncertainty.
• Lack of recent updates on clinical trial progress may raise investor concerns.

TORONTO and HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ET to report its second quarter 2022 financial results and operational highlights.

To access the call, please dial (877) 407-9716 from the United States or (201) 493-6779 internationally, followed by the conference ID: 13723601. To access the live webcast, please go visit http://public.viavid.com/index.php?id=146693. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When will Medicenna report its second quarter 2022 financial results?

Medicenna will report its second quarter 2022 financial results on November 12, 2021.

How can I access the Medicenna conference call?

You can access the conference call by dialing (877) 407-9716 from the US or (201) 493-6779 internationally, using conference ID: 13723601.

What is MDNA's focus?

MDNA focuses on the development of novel immunotherapies, particularly Superkines for cancer treatment.

Are there any updates on MDNA55 or MDNA11?

The press release did not provide recent updates on the clinical progress of MDNA55 or MDNA11.